Clinical phenotypes and quality of life to define post-COVID-19 syndrome : a cluster analysis of the multinational, prospective ORCHESTRA cohort
© 2023 The Authors..
Background: Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs.
Methods: This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant of Concern (VoC), and physical and mental quality of life (QoL). Outcome of interest was identification of risk and protective factors of PCS by clinical phenotype, setting, severity of disease, treatment, and vaccination status. We used SF-36 questionnaire to assess evolution in QoL index during follow-up and unsupervised machine learning algorithms (principal component analysis, PCA) to explore symptom clusters. Severity of PCS was defined by clinical phenotype and QoL. We also used generalized linear models to analyse the impact of PCS on QoL and associated risk and preventive factors. CT registration number: NCT05097677.
Findings: Among 1796 patients enrolled, 1030 (57%) suffered from at least one symptom at 12-month. PCA identified 4 clinical phenotypes: chronic fatigue-like syndrome (CFs: fatigue, headache and memory loss, 757 patients, 42%), respiratory syndrome (REs: cough and dyspnoea, 502, 23%); chronic pain syndrome (CPs: arthralgia and myalgia, 399, 22%); and neurosensorial syndrome (NSs: alteration in taste and smell, 197, 11%). Determinants of clinical phenotypes were different (all comparisons p < 0.05): being female increased risk of CPs, NSs, and CFs; chronic pulmonary diseases of REs; neurological symptoms at SARS-CoV-2 diagnosis of REs, NSs, and CFs; oxygen therapy of CFs and REs; and gastrointestinal symptoms at SARS-CoV-2 diagnosis of CFs. Early treatment of SARS-CoV-2 infection with monoclonal Ab (all clinical phenotypes), corticosteroids therapy for mild/severe cases (NSs), and SARS-CoV-2 vaccination (CPs) were less likely to be associated to PCS (all comparisons p < 0.05). Highest reduction in QoL was detected in REs and CPs (43.57 and 43.86 vs 57.32 in PCS-negative controls, p < 0.001). Female sex (p < 0.001), gastrointestinal symptoms (p = 0.034) and renal complications (p = 0.002) during the acute infection were likely to increase risk of severe PCS (QoL <50). Vaccination and early treatment with monoclonal Ab reduced the risk of severe PCS (p = 0.01 and p = 0.03, respectively).
Interpretation: Our study provides new evidence suggesting that PCS can be classified by clinical phenotypes with different impact on QoL, underlying possible different pathogenic mechanisms. We identified factors associated to each clinical phenotype and to severe PCS. These results might help in designing pathogenesis studies and in selecting high-risk patients for inclusion in therapeutic and management clinical trials.
Funding: The study received funding from the Horizon 2020 ORCHESTRA project, grant 101016167; from the Netherlands Organisation for Health Research and Development (ZonMw), grant 10430012010023; from Inserm, REACTing (REsearch & ACtion emergING infectious diseases) consortium and the French Ministry of Health, grant PHRC 20-0424.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
EClinicalMedicine - 62(2023) vom: 28. Aug., Seite 102107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gentilotti, Elisa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 09.11.2023 published: Electronic-eCollection ClinicalTrials.gov: NCT05097677 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.eclinm.2023.102107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361524609 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361524609 | ||
| 003 | DE-627 | ||
| 005 | 20231226085327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eclinm.2023.102107 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1205.xml |
| 035 | |a (DE-627)NLM361524609 | ||
| 035 | |a (NLM)37654668 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gentilotti, Elisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical phenotypes and quality of life to define post-COVID-19 syndrome |b a cluster analysis of the multinational, prospective ORCHESTRA cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT05097677 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Background: Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs | ||
| 520 | |a Methods: This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant of Concern (VoC), and physical and mental quality of life (QoL). Outcome of interest was identification of risk and protective factors of PCS by clinical phenotype, setting, severity of disease, treatment, and vaccination status. We used SF-36 questionnaire to assess evolution in QoL index during follow-up and unsupervised machine learning algorithms (principal component analysis, PCA) to explore symptom clusters. Severity of PCS was defined by clinical phenotype and QoL. We also used generalized linear models to analyse the impact of PCS on QoL and associated risk and preventive factors. CT registration number: NCT05097677 | ||
| 520 | |a Findings: Among 1796 patients enrolled, 1030 (57%) suffered from at least one symptom at 12-month. PCA identified 4 clinical phenotypes: chronic fatigue-like syndrome (CFs: fatigue, headache and memory loss, 757 patients, 42%), respiratory syndrome (REs: cough and dyspnoea, 502, 23%); chronic pain syndrome (CPs: arthralgia and myalgia, 399, 22%); and neurosensorial syndrome (NSs: alteration in taste and smell, 197, 11%). Determinants of clinical phenotypes were different (all comparisons p < 0.05): being female increased risk of CPs, NSs, and CFs; chronic pulmonary diseases of REs; neurological symptoms at SARS-CoV-2 diagnosis of REs, NSs, and CFs; oxygen therapy of CFs and REs; and gastrointestinal symptoms at SARS-CoV-2 diagnosis of CFs. Early treatment of SARS-CoV-2 infection with monoclonal Ab (all clinical phenotypes), corticosteroids therapy for mild/severe cases (NSs), and SARS-CoV-2 vaccination (CPs) were less likely to be associated to PCS (all comparisons p < 0.05). Highest reduction in QoL was detected in REs and CPs (43.57 and 43.86 vs 57.32 in PCS-negative controls, p < 0.001). Female sex (p < 0.001), gastrointestinal symptoms (p = 0.034) and renal complications (p = 0.002) during the acute infection were likely to increase risk of severe PCS (QoL <50). Vaccination and early treatment with monoclonal Ab reduced the risk of severe PCS (p = 0.01 and p = 0.03, respectively) | ||
| 520 | |a Interpretation: Our study provides new evidence suggesting that PCS can be classified by clinical phenotypes with different impact on QoL, underlying possible different pathogenic mechanisms. We identified factors associated to each clinical phenotype and to severe PCS. These results might help in designing pathogenesis studies and in selecting high-risk patients for inclusion in therapeutic and management clinical trials | ||
| 520 | |a Funding: The study received funding from the Horizon 2020 ORCHESTRA project, grant 101016167; from the Netherlands Organisation for Health Research and Development (ZonMw), grant 10430012010023; from Inserm, REACTing (REsearch & ACtion emergING infectious diseases) consortium and the French Ministry of Health, grant PHRC 20-0424 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Long-term sequelae | |
| 650 | 4 | |a Post-COVID syndrome | |
| 650 | 4 | |a Prediction model | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Górska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Tami, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Gusinow, Roy |e verfasserin |4 aut | |
| 700 | 1 | |a Mirandola, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Baño, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Palacios Baena, Zaira R |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Hasenauer, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes-Rafegas, Iris |e verfasserin |4 aut | |
| 700 | 1 | |a Righi, Elda |e verfasserin |4 aut | |
| 700 | 1 | |a Caroccia, Natascia |e verfasserin |4 aut | |
| 700 | 1 | |a Cataudella, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquini, Zeno |e verfasserin |4 aut | |
| 700 | 1 | |a Osmo, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Del Piccolo, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Savoldi, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar-Singh, Samir |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzaferri, Fulvia |e verfasserin |4 aut | |
| 700 | 1 | |a Caponcello, Maria Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer, Gerolf |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Gabriel Levy |e verfasserin |4 aut | |
| 700 | 0 | |a ORCHESTRA Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a De Nardo, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Malhotra, Surbhi |e verfasserin |4 aut | |
| 700 | 1 | |a Canziani, Lorenzo Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosn, Jade |e verfasserin |4 aut | |
| 700 | 1 | |a Florence, Aline-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Lafhej, Nadhem |e verfasserin |4 aut | |
| 700 | 1 | |a van der Gun, Bernardina T F |e verfasserin |4 aut | |
| 700 | 1 | |a Giannella, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Laouénan, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Tacconelli, Evelina |e verfasserin |4 aut | |
| 700 | 1 | |a Pinho Guedes, Mariana Nunes |e investigator |4 oth | |
| 700 | 1 | |a Maccarrone, Gaia |e investigator |4 oth | |
| 700 | 1 | |a Pezzani, Maria Diletta |e investigator |4 oth | |
| 700 | 1 | |a Sibani, Marcella |e investigator |4 oth | |
| 700 | 1 | |a Davies, Ruth Joanna |e investigator |4 oth | |
| 700 | 1 | |a Vitali, Stefania |e investigator |4 oth | |
| 700 | 1 | |a Franchina, Giorgia |e investigator |4 oth | |
| 700 | 1 | |a Tomassini, Giorgia |e investigator |4 oth | |
| 700 | 1 | |a Sciammarella, Concetta |e investigator |4 oth | |
| 700 | 1 | |a Cecchetto, Riccardo |e investigator |4 oth | |
| 700 | 1 | |a Gibellini, Davide |e investigator |4 oth | |
| 700 | 1 | |a De Toffoli, Chiara Konishi |e investigator |4 oth | |
| 700 | 1 | |a Rosini, Giulia |e investigator |4 oth | |
| 700 | 1 | |a Perlini, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Meroi, Marco |e investigator |4 oth | |
| 700 | 1 | |a Cioli Puviani, Filippo |e investigator |4 oth | |
| 700 | 1 | |a Fasan, Daniele |e investigator |4 oth | |
| 700 | 1 | |a Micheletto, Claudio |e investigator |4 oth | |
| 700 | 1 | |a Montemezzi, Stefania |e investigator |4 oth | |
| 700 | 1 | |a Cardobi, Nicolò |e investigator |4 oth | |
| 700 | 1 | |a Vantini, Gianluca |e investigator |4 oth | |
| 700 | 1 | |a Mazzali, Gloria |e investigator |4 oth | |
| 700 | 1 | |a Stabile, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Marcanti, Maddalena |e investigator |4 oth | |
| 700 | 1 | |a Zonta, Marco Pattaro |e investigator |4 oth | |
| 700 | 1 | |a Calì, Deborah |e investigator |4 oth | |
| 700 | 1 | |a Mason, Anna |e investigator |4 oth | |
| 700 | 1 | |a Perlini, Cinzia |e investigator |4 oth | |
| 700 | 1 | |a Gisondi, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Mongardi, Maria |e investigator |4 oth | |
| 700 | 1 | |a Sorbello, Simona |e investigator |4 oth | |
| 700 | 1 | |a Wold, Karin I |e investigator |4 oth | |
| 700 | 1 | |a Vincenti-González, María F |e investigator |4 oth | |
| 700 | 1 | |a Veloo, Alida Cm |e investigator |4 oth | |
| 700 | 1 | |a Harmsma, Valerie Pr |e investigator |4 oth | |
| 700 | 1 | |a Pantano, Daniele |e investigator |4 oth | |
| 700 | 1 | |a van der Meer, Margriet |e investigator |4 oth | |
| 700 | 1 | |a Gard, Lilli |e investigator |4 oth | |
| 700 | 1 | |a Lizarazo, Erley F |e investigator |4 oth | |
| 700 | 1 | |a Knoester, Marjolein |e investigator |4 oth | |
| 700 | 1 | |a Friedrich, Alex W |e investigator |4 oth | |
| 700 | 1 | |a Niesters, Hubert Gm |e investigator |4 oth | |
| 700 | 1 | |a Viale, Pierluigi |e investigator |4 oth | |
| 700 | 1 | |a Marzolla, Domenico |e investigator |4 oth | |
| 700 | 1 | |a Cosentino, Federica |e investigator |4 oth | |
| 700 | 1 | |a Di Chiara, Michela |e investigator |4 oth | |
| 700 | 1 | |a Fornaro, Giacomo |e investigator |4 oth | |
| 700 | 1 | |a Bonazzetti, Cecilia |e investigator |4 oth | |
| 700 | 1 | |a Tazza, Beatrice |e investigator |4 oth | |
| 700 | 1 | |a Toschi, Alice |e investigator |4 oth | |
| 700 | 1 | |a Vetamanu, Oana |e investigator |4 oth | |
| 700 | 1 | |a Giacomini, Maria Eugenia |e investigator |4 oth | |
| 700 | 1 | |a Trapani, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Marconi, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Attard, Luciano |e investigator |4 oth | |
| 700 | 1 | |a Tedeschi, Sara |e investigator |4 oth | |
| 700 | 1 | |a Gabrielli, Liliana |e investigator |4 oth | |
| 700 | 1 | |a Lazzarotto, Tiziana |e investigator |4 oth | |
| 700 | 1 | |a Olivares, Paula |e investigator |4 oth | |
| 700 | 1 | |a Castilla, Javier |e investigator |4 oth | |
| 700 | 1 | |a Vélez, Javier |e investigator |4 oth | |
| 700 | 1 | |a Almadana, Virginia |e investigator |4 oth | |
| 700 | 1 | |a Martín-Barrera, Lucía |e investigator |4 oth | |
| 700 | 1 | |a Martín-Gutiérrez, Ana Belén |e investigator |4 oth | |
| 700 | 1 | |a Gutiérrez-Campos, David |e investigator |4 oth | |
| 700 | 1 | |a Fernández-Regaña, Marta |e investigator |4 oth | |
| 700 | 1 | |a Silva-Campos, Ana |e investigator |4 oth | |
| 700 | 1 | |a Fernández-Riejos, Patricia |e investigator |4 oth | |
| 700 | 1 | |a García-Sánchez, M Isabel |e investigator |4 oth | |
| 700 | 1 | |a Giuliano, Carla V |e investigator |4 oth | |
| 700 | 1 | |a López, Carlota |e investigator |4 oth | |
| 700 | 1 | |a Neumann, Gabriela |e investigator |4 oth | |
| 700 | 1 | |a Camporro, Julieta |e investigator |4 oth | |
| 700 | 1 | |a de Vedia, Lautaro |e investigator |4 oth | |
| 700 | 1 | |a Agugliaro, Hugo |e investigator |4 oth | |
| 700 | 1 | |a Scipione, Gabriella |e investigator |4 oth | |
| 700 | 1 | |a Dellacasa, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Chandramouli, Balasubramanian |e investigator |4 oth | |
| 700 | 1 | |a Gioiosa, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Naranjo, Juan Mata |e investigator |4 oth | |
| 700 | 1 | |a Ortali, Maurizio |e investigator |4 oth | |
| 700 | 1 | |a Konnova, Angelina |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Akshita |e investigator |4 oth | |
| 700 | 1 | |a Smet, Mathias |e investigator |4 oth | |
| 700 | 1 | |a Hotterbeekx, An |e investigator |4 oth | |
| 700 | 1 | |a Berkell, Matilda |e investigator |4 oth | |
| 700 | 1 | |a Sicuri, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Bachelet, Delphine |e investigator |4 oth | |
| 700 | 1 | |a Bouadma, Lila |e investigator |4 oth | |
| 700 | 1 | |a Cervantes-Gonzalez, Minerva |e investigator |4 oth | |
| 700 | 1 | |a Chair, Anissa |e investigator |4 oth | |
| 700 | 1 | |a Charpentier, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Chenard, Léo |e investigator |4 oth | |
| 700 | 1 | |a Descamps, Diane |e investigator |4 oth | |
| 700 | 1 | |a Doan, Hang |e investigator |4 oth | |
| 700 | 1 | |a Duval, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Esposito-Farese, Marina |e investigator |4 oth | |
| 700 | 1 | |a Hoffmann, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Kafif, Ouifiya |e investigator |4 oth | |
| 700 | 1 | |a Le Hingrat, Quentin |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t EClinicalMedicine |d 2018 |g 62(2023) vom: 28. Aug., Seite 102107 |w (DE-627)NLM289300495 |x 2589-5370 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g day:28 |g month:08 |g pages:102107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eclinm.2023.102107 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |b 28 |c 08 |h 102107 | ||